What’s new in diabetes drugs

Two classes of drugs have gotten much attention lately.

Watch TV lately, and you may have noticed a slew of advertisements for two classes of diabetes drugs — GLP-1 receptor agonists and SGLT-2 inhibitors. Why are these medications being marketed so heavily? Sure, these new drugs add significant revenue to pharmaceutical companies. But they also offer health benefits beyond just keeping blood sugar levels controlled.

Growing problem

Type 2 diabetes (by far the most common type) remains a serious health risk for many Americans, especially older adults. About 34.2 million adults have type 2 diabetes, according to the CDC. Based on current trends, the CDC predicts that one in five American adults will have diabetes by 2025, and the number could reach one in three by 2050.

As a service to our readers, Harvard Health Publishing provides access to our library of archived content.
Please note the date of last review or update on all articles. No content on this site, regardless of date,
should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

More Info

By Betty C. Giordano

Welcome to my site. My name is Betty C. Giordano and I am a blogger of everything related to mobile, news, events and reality in general. I hope you enjoy reading my content.

Leave a Reply